Elucidating Novel AAV/SERCA2a Gene Therapy for the Treatment of Duchenne Cardiomyopathy

Time: 9:30 am
day: Conference Day 1


  • Cardiomyopathy associated with Duchenne continues to cause morbidity and mortality in affected patients
  • Directed gene therapy to treat cardiomyopathy has not been available yet
  • Delivery of AAV/SERCA2a in patients with cardiomyopathy is a promising strategy for improving the lives of patients in need